Harry F. Hixson Jr., Ph.D. / Chairman of the Board & Chief Executive Officer
Dr. Hixson serves as the company's Chief Executive Officer and has served as Chairman of the Board of Directors since 2003. He recently served on the Board of directors of BrainCells, Inc., a biopharmaceutical company focused on central nervous system drug development, where he was Chief Executive Officer from July 2004 until September 2005. Dr. Hixson served as Chief Executive Officer of Elitra Pharmaceuticals, Inc., a biopharmaceutical company focused on anti-infective drug development, from February 1998 until May 2003. He served as President and Chief Operating Officer of Amgen Inc., and was a member of its board of directors from 1988 to 1991. Prior to Amgen, Dr. Hixson held various management positions with Abbott Laboratories, including Vice President, Diagnostic Products Business Group, and Vice President, Research and Development, in the Diagnostics Division. Dr. Hixson also is a Director of Arena Pharmaceuticals, Inc. Dr. Hixson received his Ph.D. in Physical Biochemistry from Purdue University and an M.B.A. from the University of Chicago.
William Welch, M.B.A. / President and Chief Operating Officer
Mr. Welch was recently appointed to serve as President and Chief Operating Officer. Since January 2011, he was Senior Vice President, Diagnostics. Prior to joining Sequenom, Mr. Welch was a consultant to molecular diagnostic companies in the personalized medicine sector. From August 2005 to September 2009 Mr. Welch was Senior Vice President and Chief Commercial Officer at Monogram Biosciences, where he led sales, marketing, commercial operations and pharma alliances for its oncology and virology businesses. Prior to Monogram, Mr. Welch was Vice President of Sales and Marketing at La Jolla Pharmaceuticals and Vice President of Global Marketing at Dade Behring MicroScan. Mr. Welch entered the healthcare industry with Abbott Laboratories where he held positions of increasing responsibility including general management. Mr. Welch received his BS in Chemical Engineering from University of California at Berkeley and an M.B.A. from Harvard University.
Ronald M. Lindsay, Ph.D. / Executive Vice President, Strategic Planning
Dr. Lindsay serves as Sequenom's Executive Vice President, Strategic Planning, previously serving as Executive Vice President of Research and Development. Dr. Lindsay has been a Director since 2003. He served as Vice President, Research and Development, and Chief Science Officer of diaDexus Inc., a biotechnology company, from 2000 to January 2004. From 1997 through 2000, Dr. Lindsay served in various senior management roles with Millennium Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 to 1997, Dr. Lindsay served in various roles with Regeneron Pharmaceuticals Inc., of which he was a founding scientist. He is a director of Arqule Inc., and HistoRx Inc. and received his Ph.D. in Biochemistry from the University of Calgary.
Dirk van den Boom, Ph.D. / Executive Vice President, Research & Development and Chief Technology Officer
Dr. van den Boom serves as Sequenom's Executive Vice President, Research & Development and Chief Technology Officer. From August 2010 until December 2012, he was Senior Vice President of Research and Development of Sequenom. From October 2009 to August 2010, Dr. van den Boom served as vice president, research and development of Sequenom. Dr. van den Boom joined Sequenom in 1998 in the company’s Hamburg offices, subsequently he served in various management roles within the Sequenom R&D department. He received his Ph.D. in Biochemistry/Molecular Biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry. Dr. van den Boom has co-authored more than 50 scientific articles and is inventor on 48 patents/patent applications.
Paul V. Maier, MBA / Chief Financial Officer
Mr. Maier serves as Sequenom's chief financial officer. Mr. Maier served as senior vice president and chief financial officer of Ligand Pharmaceuticals Incorporated from 1992 until January 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. During his tenure at Ligand, Mr. Maier helped raise over $1 billion in equity and debt financings. Prior to Ligand, Mr. Maier spent six years in various management and finance positions at ICN Pharmaceuticals. Mr. Maier currently serves as a director of Apricus Biosciences, Talon Therapeutics, Pure Bioscience, and International Stem Cell Corporation. Mr. Maier received his M.B.A. from Harvard University.
Allan T. Bombard, M.D. / Chief Medical Officer
Allan T. Bombard, M.D. is chief medical officer, Sequenom, Inc. as well as visiting professor, obstetrics and gynecology, Albert Einstein College of Medicine and Clinical Professor at the University of California San Diego.
Prior to joining Sequenom, Dr. Bombard was chief executive officer, Lenetix Medical Screening Laboratories, Inc. in Mineola, New York, where he transitioned from his role as chief medical Officer, Sharp Mary Birch Hospital in San Diego, CA. Before joining Sharp Healthcare Dr. Bombard was senior vice president, chair and residency program director, department of Ob/Gyn at Lutheran Medical Center, Brooklyn, NY. Dr. Bombard came to Lutheran Medical Center from Aetna, Inc., where he served as the Western U.S. medical director for women’s health. Before working for Aetna, he served as professor & director, reproductive genetics, department of Ob/Gyn & women’s health at Montefiore Medical Center and the Albert Einstein College of Medicine in Bronx, New York. He attained the academic rank of professor at the medical school in 1997.
Dr. Bombard received his Bachelor of Arts degree from Colgate University, his Doctor of Medicine degree from the George Washington University, and his Masters in Business Administration from the University of San Diego. He completed a residency in Ob/Gyn at the Wilford Hall USAF Medical Center in San Antonio, Texas, and his fellowship in Clinical Genetics at Northwestern University in Chicago, Illinois. Dr. Bombard is board certified in both Clinical Genetics as well as Obstetrics & Gynecology.
Dr. Bombard retired from the USAF Reserves in 2002 with the rank of Colonel and served in Operation Desert Storm. He is a Founding Fellow of the American College of Medical Genetics, a Fellow of the American College of Obstetricians & Gynecologists, a member of the American Medical Association, and a life member of the American College of Physician Executives. He serves on a number of national professional committees and has lectured extensively on a variety of women’s health issues including genetic counseling, prenatal screening & diagnosis, the business of medicine, and BRCA screening. His articles have appeared in peer-reviewed medical journals such as the Lancet and the American Journal of Obstetrics & Gynecology.
Charles R. Cantor, Ph.D. / Chief Scientific Officer
Dr. Cantor joined the company as chief scientific officer in 1998. He was previously the chair and professor of the department of biomedical engineering and biophysics, and director of the Center for Advanced Biotechnology at Boston University. Prior to that time, Dr. Cantor held positions at Columbia University and the University of California, Berkeley. He was also director of the Human Genome Center Project of the Department of Energy at Lawrence Berkeley Laboratory. A world-renowned scientist, Dr. Cantor is a consultant to more than 16 biotech firms, has published more than 400 peer reviewed articles, been granted 54 US patents, and co-authored a three-volume textbook on Biophysical Chemistry. He published the first textbook on genomics entitled, Genomics: The Science and Technology of the Human Genome Project.
Michael Monko, M.B.A. / Senior Vice President, Genetic Analysis
Mr. Michael Monko joined Sequenom in August 2006. Mr. Monko has 20 years of life science sales and marketing experience. He served as vice president of sales for Upstate/Chemicon with global sales and management responsibility for more than 100 sales, service and support employees. Previously, he served 19 years at Invitrogen Corporation with a progressive and accomplished career in sales, beginning as a representative and culminating as senior director, sales force effectiveness.
Mr. Monko earned an M.B.A. from Babson College and B.S. in biochemistry from University of New Hampshire.
Bill Bowen, J.D. / Senior Vice President and General Counsel
Mr. Bowen has served as Senior Vice President and General Counsel at Sequenom since October 2012. Prior to his appointment at Sequenom, he served as Senior Vice President and General Counsel at Gen-Probe Incorporated, a San Diego-based molecular diagnostics company. Prior to joining Gen-Probe, Mr. Bowen was a business litigation partner at Luce Forward Hamilton & Scripps, LLP. Mr. Bowen received his J.D. from the University of Virginia, School of Law and a bachelor’s degree in management from the University of Virginia.
Robin Weiner / Senior Vice President, Regulatory Affairs & Quality
Robin Weiner serves as the company's senior vice president of regulatory affairs and quality.
Prior to joining Sequenom, Ms. Weiner was an independent regulatory consultant to biotechnology companies, focusing on regulatory strategy, product submissions and quality management systems.
From 2004 to 2007, Ms. Weiner served as vice president regulatory & government affairs at Biosite Incorporated, responsible for leading Biosite’s worldwide product approvals and regulatory compliance activities.
Prior to Biosite, Ms. Weiner was with Quidel Corporation, most recently serving as vice president, clinical and regulatory affairs.
Prior to joining Quidel, she held research positions at the Scripps Clinic and Research Foundation and the University of California, San Diego.
Ms. Weiner holds a bachelor’s degree from the University of California, San Diego and a master’s degree in business administration from National University.
Carolyn D. Beaver / Vice President and Chief Accounting Officer
Ms. Beaver serves as Sequenom’s Vice President and Chief Accounting Officer. She was previously employed with Beckman Coulter, Inc., a global biomedical testing manufacturer since 2005, and served as Corporate Vice President, Controller and Chief Accounting Officer. Since its acquisition by Danaher Corp. in June 2011, Ms. Beaver continued to serve at Beckman Coulter, Inc. as the Corporate Vice President, Controller. From 1987 until 2002, Ms. Beaver was a partner with KPMG LLP. Ms. Beaver also currently serves as a director of Commerce National Bank, a position she has held since 2005. Ms. Beaver holds a B.S. in Accounting from California State Polytechnic University, Pomona and is a licensed CPA.
Alisa Judge / Vice President, Human Resources
Ms. Alisa Judge brings over 20 years of human resources experience having previously served as vice president of human resources at Claritas, a division of the Nielsen Company, the world's leading provider of marketing information and audience measurement, prior to Claritas, Ms. Judge held the same role for GKN Aerospace Chem-tronics, a leading global supplier to the world's automotive and aerospace manufacturers. Prior to GKN, she was Director of Global Staffing and Retention at Invitrogen Corp., a global biotech manufacturer based in Carlsbad, Calif. She also held the title of Vice President, Human Resources, at Advanced Marketing Services, Inc., where she spent 10 years. The San Diego-based company provided wholesaling and distribution services to book retailers.